-
1
-
-
0018967338
-
The global eradication of smallpox
-
Fenner F. 1980. The global eradication of smallpox. Med. J. Aust. 1:455.
-
(1980)
Med. J. Aust.
, vol.1
, pp. 455
-
-
Fenner, F.1
-
2
-
-
0002766490
-
The clinical features of smallpox
-
World Health Organization, Geneva, Switzerland
-
Fenner F, Henderson DA, Arista I, Jerzek Z, Ladnyi ID. 1988. The clinical features of smallpox. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
-
(1988)
Smallpox and its Eradication
-
-
Fenner, F.1
Henderson, D.A.2
Arista, I.3
Jerzek, Z.4
Ladnyi, I.D.5
-
3
-
-
84874044394
-
-
London, United Kingdom, A. Churchill Ltd.
-
Dixon CW. 1962. Smallpox. J. & A. Churchill Ltd., London, United Kingdom.
-
(1962)
Smallpox. J.
-
-
Dixon, C.W.1
-
4
-
-
0036631801
-
Studies in smallpox and vaccination. 1913
-
Hanna W, Baxby D. 2002. Studies in smallpox and vaccination. 1913. Rev. Med. Virol. 12:201-209.
-
(2002)
Rev. Med. Virol
, vol.12
, pp. 201-209
-
-
Hanna, W.1
Baxby, D.2
-
5
-
-
66149119341
-
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification
-
Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817- 1822.
-
(2009)
Antimicrob. Agents Chemother
, vol.53
, pp. 1817-1822
-
-
Jordan, R.1
Goff, A.2
Frimm, A.3
Corrado, M.L.4
Hensley, L.E.5
Byrd, C.M.6
Mucker, E.7
Shamblin, J.8
Bolken, T.C.9
Wlazlowski, C.10
Johnson, W.11
Chapman, J.12
Twenhafel, N.13
Tyavanagimatt, S.14
Amantana, A.15
Chinsangaram, J.16
Hruby, D.E.17
Huggins, J.18
-
6
-
-
43649089767
-
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model
-
Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R. 2008. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antivir. Res. 79:121-127.
-
(2008)
Antivir. Res.
, vol.79
, pp. 121-127
-
-
Nalca, A.1
Hatkin, J.M.2
Garza, N.L.3
Nichols, D.K.4
Norris, S.W.5
Hruby, D.E.6
Jordan, R.7
-
7
-
-
34249742507
-
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection
-
Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, Siirin M, Newman PC, Da Rosa AP, Tesh RB. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768 -773.
-
(2007)
Am. J. Trop. Med. Hyg.
, vol.76
, pp. 768-773
-
-
Sbrana, E.1
Jordan, R.2
Hruby, D.E.3
Mateo, R.I.4
Xiao, S.Y.5
Siirin, M.6
Newman, P.C.7
Da Rosa, A.P.8
Tesh, R.B.9
-
8
-
-
80052279730
-
Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus
-
Smith SK, Self J, Weiss S, Carroll D, Braden Z, Regnery RL, Davidson W, Jordan R, Hruby DE, Damon IK. 2011. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J. Virol. 85:9176 -9187.
-
(2011)
J. Virol
, vol.85
, pp. 9176-9187
-
-
Smith, S.K.1
Self, J.2
Weiss, S.3
Carroll, D.4
Braden, Z.5
Regnery, R.L.6
Davidson, W.7
Jordan, R.8
Hruby, D.E.9
Damon, I.K.10
-
9
-
-
26444587116
-
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge
-
Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139 -13149.
-
(2005)
J. Virol
, vol.79
, pp. 13139-13149
-
-
Yang, G.1
Pevear, D.C.2
Davies, M.H.3
Collett, M.S.4
Bailey, T.5
Rippen, S.6
Barone, L.7
Burns, C.8
Rhodes, G.9
Tohan, S.10
Huggins, J.W.11
Baker, R.O.12
Buller, R.L.13
Touchette, E.14
Waller, K.15
Schriewer, J.16
Neyts, J.17
Declercq, E.18
Jones, K.19
Hruby, D.20
Jordan, R.21
more..
-
10
-
-
35848968505
-
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses
-
Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER. 2007. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51:4118-4124.
-
(2007)
Antimicrob. Agents Chemother
, vol.51
, pp. 4118-4124
-
-
Quenelle, D.C.1
Prichard, M.N.2
Keith, K.A.3
Hruby, D.E.4
Jordan, R.5
Painter, G.R.6
Robertson, A.7
Kern, E.R.8
-
11
-
-
67049136160
-
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246
-
Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, Hruby D. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620 -2625.
-
(2009)
Antimicrob. Agents Chemother
, vol.53
, pp. 2620-2625
-
-
Huggins, J.1
Goff, A.2
Hensley, L.3
Mucker, E.4
Shamblin, J.5
Wlazlowski, C.6
Johnson, W.7
Chapman, J.8
Larsen, T.9
Twenhafel, N.10
Karem, K.11
Damon, I.K.12
Byrd, C.M.13
Bolken, T.C.14
Jordan, R.15
Hruby, D.16
-
12
-
-
6344282192
-
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox
-
Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, Huggins JW. 2004. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U. S. A. 101:15196 -15200.
-
(2004)
Proc. Natl. Acad. Sci. U. S. A.
, vol.101
, pp. 15196-15200
-
-
Jahrling, P.B.1
Hensley, L.E.2
Martinez, M.J.3
Leduc, J.W.4
Rubins, K.H.5
Relman, D.A.6
Huggins, J.W.7
-
13
-
-
80053611041
-
Progression of pathogenic events in cynomolgus macaques infected with variola virus
-
doi:10.1371/journal.pone .0024832
-
Wahl-Jensen V, Cann JA, Rubins KH, Huggins JW, Fisher RW, Johnson AJ, de Kok-Mercado F, Larsen T, Raymond JL, Hensley LE, Jahrling PB. 2011. Progression of pathogenic events in cynomolgus macaques infected with variola virus. PLoS One 6:e24832. doi:10.1371/journal.pone .0024832.
-
(2011)
PLoS One
, vol.6
-
-
Wahl-Jensen, V.1
Cann, J.A.2
Rubins, K.H.3
Huggins, J.W.4
Fisher, R.W.5
Johnson, A.J.6
De Kok-Mercado, F.7
Larsen, T.8
Raymond, J.L.9
Hensley, L.E.10
Jahrling, P.B.11
-
14
-
-
62949084687
-
In vitro efficacy of ST246 against smallpox and monkeypox
-
Smith SK, Olson VA, Karem KL, Jordan R, Hruby DE, Damon IK. 2009. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob. Agents Chemother. 53:1007-1012.
-
(2009)
Antimicrob. Agents Chemother
, vol.53
, pp. 1007-1012
-
-
Smith, S.K.1
Olson, V.A.2
Karem, K.L.3
Jordan, R.4
Hruby, D.E.5
Damon, I.K.6
-
15
-
-
80052109447
-
Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox
-
Johnson RF, Yellayi S, Cann JA, Johnson A, Smith AL, Paragas J, Jahrling PB, Blaney JE. 2011. Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox. Virology 418:102-112.
-
(2011)
Virology
, vol.418
, pp. 102-112
-
-
Johnson, R.F.1
Yellayi, S.2
Cann, J.A.3
Johnson, A.4
Smith, A.L.5
Paragas, J.6
Jahrling, P.B.7
Blaney, J.E.8
-
16
-
-
37849005004
-
Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge
-
Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. 2008. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26:581-588.
-
(2008)
Vaccine
, vol.26
, pp. 581-588
-
-
Marriott, K.A.1
Parkinson, C.V.2
Morefield, S.I.3
Davenport, R.4
Nichols, R.5
Monath, T.P.6
-
17
-
-
3142527261
-
SmallpoxDNAvaccine protects nonhuman primates against lethal monkeypox
-
Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, Schmaljohn CS, Schmaljohn AL, Jahrling PB. 2004. SmallpoxDNAvaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433- 4443.
-
(2004)
J. Virol
, vol.78
, pp. 4433-4443
-
-
Hooper, J.W.1
Thompson, E.2
Wilhelmsen, C.3
Zimmerman, M.4
Ichou, M.A.5
Steffen, S.E.6
Schmaljohn, C.S.7
Schmaljohn, A.L.8
Jahrling, P.B.9
-
19
-
-
77952642017
-
Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects
-
Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE. 2010. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 54:2560 -2566.
-
(2010)
Antimicrob. Agents Chemother
, vol.54
, pp. 2560-2566
-
-
Jordan, R.1
Chinsangaram, J.2
Bolken, T.C.3
Tyavanagimatt, S.R.4
Tien, D.5
Jones, K.F.6
Frimm, A.7
Corrado, M.L.8
Pickens, M.9
Landis, P.10
Clarke, J.11
Marbury, T.C.12
Hruby, D.E.13
-
20
-
-
0035216180
-
Ways to fit a PK model with some data below the quantification limit
-
Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
-
(2001)
J. Pharmacokinet. Pharmacodyn
, vol.28
, pp. 481-504
-
-
Beal, S.L.1
-
21
-
-
80051681535
-
Comparison of the safety and pharmacokinetics of ST-246(R) after i.v. Infusion or oral administration in mice, rabbits and monkeys
-
doi:10.1371/journal .pone.0023237
-
Chen Y, Amantana A, Tyavanagimatt SR, Zima D, Yan XS, Kasi G, Weeks M, Stone MA, Weimers WC, Samuel P, Tan Y, Jones KF, Lee DR, Kickner SS, Saville BM, Lauzon M, McIntyre A, Honeychurch KM, Jordan R, Hruby DE, Leeds JM. 2011. Comparison of the safety and pharmacokinetics of ST-246(R) after i.v. infusion or oral administration in mice, rabbits and monkeys. PLoS One 6:e23237. doi:10.1371/journal .pone.0023237.
-
(2011)
PLoS One
, vol.6
-
-
Chen, Y.1
Amantana, A.2
Tyavanagimatt, S.R.3
Zima, D.4
Yan, X.S.5
Kasi, G.6
Weeks, M.7
Stone, M.A.8
Weimers, W.C.9
Samuel, P.10
Tan, Y.11
Jones, K.F.12
Lee, D.R.13
Kickner, S.S.14
Saville, B.M.15
Lauzon, M.16
McIntyre, A.17
Honeychurch, K.M.18
Jordan, R.19
Hruby, D.E.20
Leeds, J.M.21
more..
-
23
-
-
84865404323
-
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers
-
Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE. 2012. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob. Agents Chemother. 56:4900-4905.
-
(2012)
Antimicrob. Agents Chemother
, vol.56
, pp. 4900-4905
-
-
Chinsangaram, J.1
Honeychurch, K.M.2
Tyavanagimatt, S.R.3
Leeds, J.M.4
Bolken, T.C.5
Jones, K.F.6
Jordan, R.7
Marbury, T.8
Ruckle, J.9
Mee-Lee, D.10
Ross, E.11
Lichtenstein, I.12
Pickens, M.13
Corrado, M.14
Clarke, J.M.15
Frimm, A.M.16
Hruby, D.E.17
-
24
-
-
0029951033
-
A size standard for pharmacokinetics
-
Holford NH. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329 -332.
-
(1996)
Clin. Pharmacokinet
, vol.30
, pp. 329-332
-
-
Holford, N.H.1
-
25
-
-
70449647008
-
Proportional hazards tests and diagnostics based on weighted residuals
-
Grambsch PM, Therneau TM. 1994. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526.
-
(1994)
Biometrika
, vol.81
, pp. 515-526
-
-
Grambsch, P.M.1
Therneau, T.M.2
-
27
-
-
0028792083
-
First-time-in-human dose selection: Allometric thoughts and perspectives
-
Boxenbaum H, DiLea C. 1995. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol. 35:957-966.
-
(1995)
J. Clin. Pharmacol
, vol.35
, pp. 957-966
-
-
Boxenbaum, H.1
Dilea, C.2
-
28
-
-
84866079822
-
FDA experience with medical countermeasures under the animal rule
-
doi:10.1155/2012/507571
-
Aebersold P. 2012. FDA experience with medical countermeasures under the animal rule. Adv. Prev. Med. 2012:507571. doi:10.1155/2012/507571.
-
(2012)
Adv. Prev. Med.
, vol.2012
, pp. 507571
-
-
Aebersold, P.1
-
29
-
-
67650500264
-
Raxibacumab for the treatment of inhalational anthrax
-
Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 361:135-144.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 135-144
-
-
Migone, T.S.1
Subramanian, G.M.2
Zhong, J.3
Healey, L.M.4
Corey, A.5
Devalaraja, M.6
Lo, L.7
Ullrich, S.8
Zimmerman, J.9
Chen, A.10
Lewis, M.11
Meister, G.12
Gillum, K.13
Sanford, D.14
Mott, J.15
Bolmer, S.D.16
-
30
-
-
69449088646
-
The animal rule and emerging infections: The role of clinical pharmacology in determining an effective dose
-
Bergman KL. 2009. The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose. Clin. Pharmacol. Ther. 86:328 -331.
-
(2009)
Clin. Pharmacol. Ther
, vol.86
, pp. 328-331
-
-
Bergman, K.L.1
|